We further discuss the potential impact and clinical implications of somatic mutations in UGT genes on the capacity of cancer cells to metabolize anticancer drugs and pro/anti-cancer signaling molecules through the UGT conjugation pathway. The gene discussed is SLC35A2; the disease is cancer.